S. Claiborne Johnston

Dr. S. Claiborne Johnston

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SJS. Claiborne Johnston
S. Claiborne Johnston
JEJ. Donald Easton
J. Donald Easton
MFMary Farrant
Mary Farrant
WBWilliam Barsan
William Barsan
RCRobin A. Conwit
Robin A. Conwit
YPYuko Y. Palesch
Yuko Y. Palesch
Combination antiplatelet therapy with clopidogrel and aspirin may reduce the rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient ischemic attack (TIA). A trial of combination antiplatelet therapy in a Chinese population has shown a reduction in the risk of recurrent stroke. We tested this combination in an international population. In a randomized trial, we assigned patients with minor ischemic stroke or high-risk TIA to receive either clopidogrel at a loading dose of 600 mg on day 1, followed by 75 mg per day, plus aspirin (at a dose of 50 to 325 mg per day) or the same range of doses of aspirin alone. The dose of aspirin in each group was selected by the site investigator. The primary efficacy outcome in a time-to-event analysis was the risk of a composite of major ischemic events, which was defined as ischemic stroke, myocardial infarction, or death from an ischemic vascular event, at 90 days. A total of 4881 patients were enrolled at 269 international sites. The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days. Major ischemic events occurred in 121 of 2432 patients (5.0%) receiving clopidogrel plus aspirin and in 160 of 2449 patients (6.5%) receiving aspirin plus placebo (hazard ratio, 0.75; 95% confidence interval [CI], 0.59 to 0.95; P=0.02), with most events occurring during the first week after the initial event. Major hemorrhage occurred in 23 patients (0.9%) receiving clopidogrel plus aspirin and in 10 patients (0.4%) receiving aspirin plus placebo (hazard ratio, 2.32; 95% CI, 1.10 to 4.87; P=0.02). In patients with minor ischemic stroke or high-risk TIA, those who received a combination of clopidogrel and aspirin had a lower risk of major ischemic events but a higher risk of major hemorrhage at 90 days than those who received aspirin alone. (Funded by the National Institute of Neurological Disorders and Stroke; POINT ClinicalTrials.gov number, NCT00991029.)

1 January 2007 in The Lancet
Verified
Journal Article
Closed access
SJS. Claiborne Johnston
S. Claiborne Johnston
PRPeter M Rothwell
Peter M Rothwell
MNMai N Nguyen-Huynh
Mai N Nguyen-Huynh
MGMatthew F Giles
Matthew F Giles
JEJacob S Elkins
Jacob S Elkins
SSStephen Sidney
Stephen Sidney

1 April 2009 in The Lancet Neurology
Verified
Journal Article
Closed access
SJS. Claiborne Johnston
S. Claiborne Johnston
SMShanthi Mendis
Shanthi Mendis
CMColin D Mathers
Colin D Mathers

1 January 2008 in Stroke
Verified
Journal Article
Closed access
SJS. Claiborne Johnston
S. Claiborne Johnston
CDChristopher F. Dowd
Christopher F. Dowd
RHRandall T. Higashida
Randall T. Higashida
MLMichael T. Lawton
Michael T. Lawton
GDGary R. Duckwiler
Gary R. Duckwiler
DGDaryl R. Gress
Daryl R. Gress
Background and Purpose— The primary purpose of intracranial aneurysm treatment is to prevent rupture. Risk factors for rupture after aneurysm treatment have not been clearly established, and the need to completely occlude aneurysms is debated. Methods— The Cerebral Aneurysm Rerupture After Treatment (CARAT) study is an ambidirectional cohort study of all patients with ruptured intracranial aneurysms treated with coil embolization or surgical clipping at 9 high-volume centers in the United States from 1996 to 1998. All subjects were followed through 2005, and all potential reruptures were adjudicated by a panel of 3 specialists without knowledge of the initial treatment or aneurysm characteristics. Degree of aneurysm occlusion post-treatment was evaluated as a predictor of nonprocedural rerupture in univariate Kaplan–Meier analysis (log-rank test) and in a Cox proportional-hazards model after adjustment for potential confounders and censoring at time of retreatment. Results— Among 1001 patients during a mean of 4.0 years follow-up, there were 19 postprocedural reruptures; median time to rerupture was 3 days and 58% led to death. The degree of aneurysm occlusion after treatment was strongly associated with risk of rerupture (overall risk: 1.1% for complete occlusion, 2.9% for 91% to 99% occlusion, 5.9% for 70% to 90%, 17.6% for <70%; P <0.0001 in univariate and multivariable analysis). Overall risk of rerupture tended to be greater after coil embolization compared with surgical clipping (3.4% versus 1.3%; P =0.092), but the difference did not persist after adjustment ( P =0.83). Conclusions— Degree of aneurysm occlusion after the initial treatment is a strong predictor of the risk of subsequent rupture in patients presenting with subarachnoid hemorrhage, which justifies attempts to completely occlude aneurysms.

24 February 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LGLeslie A. Gillum
Leslie A. Gillum
CGChristopher Gouveia
Christopher Gouveia
EDE. Ray Dorsey
E. Ray Dorsey
MPMark Pletcher
Mark Pletcher
CMColin D. Mathers
Colin D. Mathers
SJS. Claiborne Johnston
S. Claiborne Johnston
An analysis of NIH funding in 1996 found that the strongest predictor of funding, disability-adjusted life-years (DALYs), explained only 39% of the variance in funding. In 1998, Congress requested that the Institute of Medicine (IOM) evaluate priority-setting criteria for NIH funding; the IOM recommended greater consideration of disease burden. We examined whether the association between current burden and funding has changed since that time. We analyzed public data on 2006 NIH funding for 29 common conditions. Measures of US disease burden in 2004 were obtained from the World Health Organization's Global Burden of Disease study and national databases. We assessed the relationship between disease burden and NIH funding dollars in univariate and multivariable log-linear models that evaluated all measures of disease burden. Sensitivity analyses examined associations with future US burden, current and future measures of world disease burden, and a newly standardized NIH accounting method. In univariate and multivariable analyses, disease-specific NIH funding levels increased with burden of disease measured in DALYs (p = 0.001), which accounted for 33% of funding level variation. No other factor predicted funding in multivariable models. Conditions receiving the most funding greater than expected based on disease burden were AIDS ($2474 M), diabetes mellitus ($390 M), and perinatal conditions ($297 M). Depression ($719 M), injuries ($691 M), and chronic obstructive pulmonary disease ($613 M) were the most underfunded. Results were similar using estimates of future US burden, current and future world disease burden, and alternate NIH accounting methods. Current levels of NIH disease-specific research funding correlate modestly with US disease burden, and correlation has not improved in the last decade.

1 December 2019 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
YPYuesong Pan
Yuesong Pan
JEJordan J. Elm
Jordan J. Elm
HLHao Li
Hao Li
JEJ. Donald Easton
J. Donald Easton
YWYilong Wang
Yilong Wang
SJS. Claiborne Johnston
S. Claiborne Johnston
Quiz Ref ID Dual antiplatelet therapy with the combination of clopidogrel and aspirin was shown to reduce the early risk of new stroke in patients with minor ischemic stroke or transient ischemic attack (TIA) in a Chinese population enrolled in the Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) trial.1 The efficacy of dual antiplatelet therapy was further validated in North America, Europe, Australia, and New Zealand in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial.2 However, an increase in major hemorrhage observed in the POINT trial led to concerns about bleeding risks in dual antiplatelet therapy.3 Uncertainties remained about the risks and benefits of dual antiplatelet therapy and the optimal duration of dual antiplatelet therapy for minor stroke or TIA. Moreover, the 2 trials were each moderate in size, whereas pooled-data analysis can provide more precise estimates of treatment outcomes. As the investigators from the CHANCE and POINT trials, we sought to address these questions about the risks and benefits of dual antiplatelet therapy after minor ischemic stroke or TIA by analyzing pooled individual patient–level data from the 2 trials.